2013 Fiscal Year Final Research Report
Involvement of bone marrow-derived fibrocyte in the pathogenesis of pulmonary fibrosis and the effect of newly developed anti-fibrotic agents
| Project/Area Number |
23591163
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
AZUMA Arata 日本医科大学, 医学部, 教授 (10184194)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
神尾 孝一郎 (20465305)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 特発性肺線維症 / 線維細胞 / ピルフェニドン |
|---|
| Research Abstract |
Bone marrow-derived fibrocytes reportedly play important roles in the pathogenesis of idiopathic pulmonary fibrosis. Pirfenidone (PFD) is an anti-fibrotic agent; however, its effects on fibrocytes have not been investigated. The aim of this study was to investigate whether PFD inhibits fibrocyte pool size in the lungs of bleomycin (BLM)-treated mice. To achieve this, C57BL/6 mice were treated with BLM and PFD was administered. Fibrocyte pool size in BLM-treated mice lungs was attenuated by PFD. This was also observed in a therapeutic setting. Increased chemokine (CC motif) ligand-2 (CCL2) and CCL12 production in BLM-treated mouse lungs was significantly attenuated by PFD. Fibrocyte migration toward CCL2 and chemokine (CC motif) receptor-2 expression on fibrocytes were significantly inhibited by PFD in vitro. Fibrocyte inhibition is considered a mechanism of anti-fibrotic action of PFD.
|
